Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.
Compulsory enrollment in a high-deductible health insurance plan is associated with significant delays in seeking care for macrovascular complications among people with diabetes, US research shows.